16:58 EST MiNK Therapeutics (INKT) files $150M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating
- MiNK Therapeutics reports updated clinical results on agenT-797
- MiNK Therapeutics Appoints Dr. John Holcomb as Director
- MiNK Therapeutics appoints John Holcomb to board of directors
- MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases